EXACT Sciences Corporation (NASDAQ: EXAS) today announced that stool-based DNA (sDNA) screening for colorectal cancer has been added as an approved colorectal cancer screening option to the Massachusetts Care Coordination Program (MA-CCP) of the Massachusetts Department of Public Health. The MA-CCP is a state and federally funded program for low-income men and women over age 40 seeking healthcare in Massachusetts. The program will be implemented in the first quarter of calendar 2009 as part of a state-wide effort, by over 30 community health centers across Massachusetts, to increase colorectal cancer screening among the approximately 12,000 MA-CCP participants 50 years of age and older.

“The program is very excited to be able to offer sDNA screening as an alternative to colonoscopy for patients who are unwilling or unable to complete a colonoscopy,” said Mary Lou Woodford, MBA, BSN, CCM, Women's Health Network Director for the Massachusetts Department of Public Health.

“We are gratified that sDNA technologies will be included as an option for patients in the Massachusetts program,” said Dr. Barry M. Berger, Chief Medical Officer of EXACT Sciences. “The Massachusetts program is very well developed and provides key patient navigation services and a patient support system that assists members with the logistics of screening, which has been shown in studies to be associated with high levels of patient compliance.”

About the Massachusetts Department of Public Health Care Coordination Program (CCP)

The Massachusetts Care Coordination Program (MA-CCP) of the Massachusetts Department of Public Health is a state and federally funded program for low-income men and women over age 40. The program offers a "personal touch" to the most vulnerable populations seeking healthcare in Massachusetts, offering patient navigation and case management services to all eligible members. The program focuses on ensuring that all members receive appropriate preventive care and cancer screening for some of the most preventable chronic conditions. The program focuses on compliance of national guidelines for breast cancer, cervical cancer, colorectal cancer, prostate cancer, heart disease and stroke. All members receive education about the tests that are recommended by their doctor as well as assistance with scheduling, transportation, childcare or any other barriers that may prevent successful completion of the tests.

About Colorectal Cancer

Colorectal cancer is the most deadly cancer among non-smoking men and women in the United States, and the second most deadly cancer overall. The American Cancer Society estimates that nearly 150,000 cases will be diagnosed and 50,000 deaths are anticipated in 2008 due to this disease. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low, and deaths remain high. It is estimated that roughly one-third of colorectal cancer-related deaths could be avoided if more people underwent regular screening. Early diagnosis results in a greater than 90 percent, five-year survival rate.

About EXACT Sciences Corporation

EXACT Sciences Corporation uses applied genomics to develop patient-friendly screening technologies for use in the detection of cancer. EXACT maintains an exclusive license agreement in the United States and Canada with Laboratory Corporation of America® Holdings (LabCorp®) for certain intellectual property relating to stool-based DNA screening. EXACT continues to retain rights to offer a colorectal cancer testing service itself within the United States, to develop a U.S. Food and Drug Administration cleared or approved in vitro diagnostic colorectal cancer test kit, and rights to license its colorectal cancer technologies outside of the United States and Canada. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer (a group comprised of representatives from the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy), and the American College of Radiology. The Company has 115 patents in the United States and abroad, with key intellectual property assets applicable to the field of oncology and reproductive health. EXACT Sciences is based in Marlborough, Mass.

Certain statements made in this press release that are not based on historical information are express or implied forward-looking statements relating to, among other things, EXACT Sciences' expectations concerning patient adoption of stool-based DNA screening methods for colorectal cancer and similar matters. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond EXACT Sciences' control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, EXACT Sciences' ability to secure FDA approval or clearance for any of its products; changes in FDA guidance or policy; the ability to attract prospective collaborators or other parties to enter into a collaboration, acquisition or other strategic transaction with EXACT; the ability to raise additional capital on acceptable terms; the clinical performance and market acceptance of its technologies; the reproducibility of its research results in subsequent studies and in clinical practice; sufficient investment in the sales and marketing of EXACT Sciences' technologies; the success of its strategic relationship with LabCorp; EXACT Sciences' ability to license certain technologies or obtain raw materials for its technologies; the ability to convince Medicare and other third-party payors to provide adequate reimbursement for EXACT Sciences' technologies; the ability to convince medical practitioners to order tests using EXACT Sciences' technologies; the ability to increase the performance its technologies; the ability of EXACT Sciences or LabCorp to lower the cost of stool-based DNA screening technologies through automating and simplifying key operational processes; the number of people who decide to be screened for colorectal cancer using EXACT Sciences' technologies; competition; the ability to protect EXACT Sciences' intellectual property and the cost of enforcing or defending EXACT Sciences in litigation relating to intellectual property rights; and the possibility that other companies will develop and market novel or improved methods for detecting colorectal cancer. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. EXACT Sciences undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by EXACT Sciences, see the disclosure contained in EXACT Sciences' public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC.